Organon & Co. (NYSE:OGN) Hits New 12-Month High - Should You Buy?

Key Points

• Organon shares reached a new 52-week high of $13.78, above their 50-day moving average of $13.62 and 200-day moving average of $11.38.
• Analysts remain cautious: five rate the stock Hold and two rate it Sell, resulting in a consensus “Reduce” rating and an $11.40 price target.
• Organon declared a quarterly dividend of $0.02 per share, equal to an annualized dividend of $0.08 and a 0.6% yield; institutional investors own 77.43% of the company.

Organon & Co. (NYSE:OGN - Get Free Report) shares hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $13.78 and last traded at $13.7750, with a volume of 4872488 shares trading hands. The stock had previously closed at $13.78.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered shares of Organon & Co. from a "hold (c)" rating to a "hold (c-)" rating in a report on Monday, August 3rd. Five research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus price target of $11.40.

Organon & Co. Price Performance

The firm has a fifty day moving average of $13.62 and a two-hundred day moving average of $11.38. The stock has a market capitalization of $3.62 billion, a P/E ratio of 17.89, a P/E/G ratio of 1.28 and a beta of 1.52. The company has a debt-to-equity ratio of 8.43, a current ratio of 1.95 and a quick ratio of 1.44.

Organon & Co. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a dividend of $0.02 per share. The ex-dividend date is Friday, August 14th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.'s dividend payout ratio (DPR) is currently 10.39%.

Institutional Trading of Organon & Co.

A number of hedge funds have recently bought and sold shares of OGN. Private Management Group Inc. grew its stake in Organon & Co. by 38.3% in the fourth quarter. Private Management Group Inc. now owns 4,347,073 shares of the company's stock valued at $31,169,000 after purchasing an additional 1,204,979 shares during the last quarter. California State Teachers Retirement System boosted its holdings in shares of Organon & Co. by 34.8% in the 1st quarter. California State Teachers Retirement System now owns 327,075 shares of the company's stock valued at $1,959,000 after buying an additional 84,497 shares in the last quarter. Orographic Financial Advisors LLC purchased a new stake in Organon & Co. during the first quarter valued at approximately $1,522,000. Sei Investments Co. lifted its position in Organon & Co. by 82.0% during the first quarter. Sei Investments Co. now owns 190,057 shares of the company's stock valued at $1,139,000 after acquiring an additional 85,657 shares during the last quarter. Finally, Brandes Investment Partners LP boosted its stake in Organon & Co. by 46.7% in the fourth quarter. Brandes Investment Partners LP now owns 606,499 shares of the company's stock valued at $4,349,000 after acquiring an additional 193,064 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. Company Profile

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.